Cargando…
One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
Aberrant DNA methylation, dysregulation of chromatin-modifying enzymes, and microRNAs (miRNAs) play a crucial role in haematological malignancies. These epimutations, with an impact on chromatin accessibility and transcriptional output, are often associated with genomic instability and the emergence...
Autores principales: | Kalushkova, Antonia, Nylund, Patrick, Párraga, Alba Atienza, Lennartsson, Andreas, Jernberg-Wiklund, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715477/ https://www.ncbi.nlm.nih.gov/pubmed/34968247 http://dx.doi.org/10.3390/epigenomes5040022 |
Ejemplares similares
-
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021) -
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016) -
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017) -
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
por: Agarwal, Prasoon, et al.
Publicado: (2016) -
One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome
por: Capecchi, Alice, et al.
Publicado: (2020)